Inhibrx, Inc.

Inhibrx, Inc. (INBX) priced its initial public offering on Aug 19, 2020 at $17.00 per share, within its $16.00–$18.00 range, raising $119M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $623.2M. Jefferies was lead-left underwriter, joined by Evercore ISI and Credit Suisse. Mintz advised the company and Cooley advised the underwriters.

Inhibrx, Inc. is a clinical-stage biotechnology company developing biologic therapeutic candidates built on its single domain antibody platform. It has four Phase 1 programs, three in cancer and one in Alpha-1 Antitrypsin Deficiency, led by INBRX-109, a DR5 agonist studied in chondrosarcoma and mesothelioma.

Status

IPO

Ticker

INBX

Exchange

Nasdaq Global Market

Priced

Aug 19, 2020

IPO price

$17.00

Price range

$16.00–$18.00

Raised

$119M

Market cap at IPO price

$623.2M

First filed

Jun 3, 2019

Underwriters

Jefferies, Evercore ISI and Credit Suisse

Company counsel

Mintz

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.